Tesaro Shares Multitude of Ovarian Cancer Treatment Findings at Madrid Conference

Tesaro Shares Multitude of Ovarian Cancer Treatment Findings at Madrid Conference
Half of ovarian cancer patients in a small study responded to a combination of Tesaro's Zejula and Genentech’s Avastin, according to a presentation Tesaro made at the European Society of Medical Oncology (ESMO) 2017 Meeting in Madrid. It was one of a host of presentations the company delivered on Zejula (niraparib) and another of its ovarian cancer therapies, TSR-042. The conference ran from Sept. 8-12. Among the highlights were trials exploring combinations of Zejula — approved in the U.S. in March 2017 as a maintenance therapy for women with ovarian cancer — and cancer immunotherapy drugs. Another intriguing presentation was a study suggesting that watchful waiting after a chemotherapy round for ovarian cancer is a bad treatment approach. “Zejula is the market-leading PARP inhibitor, with unsurpassed efficacy in a broad patient population and convenient, once-daily dosing,” Mary Lynne Hedley, president and chief operating officer of Tesaro, said in a press release. The drug was the focus of no fewer than six presentations. Several reported data from the Phase 3 NOVA trial (NCT01847274) in which women who had completed chemotherapy received Zejula as a maintenance therapy. The trial showed that many patients experience residual symptoms after chemotherapy. Zejula did not improve patient-reported outcomes or quality of life, the trial indicated. It did show that the drug is equally
Subscribe or to access all post and page content.


  1. Nancy B says:

    Are these options available at all cancer facilities?? I treat at MD ANDERSON in Camden, NJ. I’m still in treatment for Fallopian tube serous carcinoma; Stage IIIC. Just wondering what my treatments options are moving forward. I’m currently on Gemzar!!! I’ve been on a number of drugs and I’m just wondering with all this talk about Car-T therapy where it’s being offered.

    • Magdalena Kegel says:

      Dear Nancy,
      We at Ovarian Cancer News have no good insight into which treatments that are offered at different centers. We are not physicians, and can’t advise you on treatment matters, so I suggest that you discuss this with your physician. If you wish to participate in a clinical trial of CAR T-cells (which is not an approved treatment in faloppian tube or ovarian cancer) you could also ask your physician to help you find a suitable trial.

Leave a Comment

Your email address will not be published. Required fields are marked *